Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B | O95264 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473655 | 1.00 | MEN1 (0.34) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL5731936 | 1.00 | MEN1 (0.34) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL13076984 | 0.86 | — | — | |
| SCHEMBL12650558 | 0.84 | MEN1 (0.31) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL6057033 | 0.81 | — | — | |
| SCHEMBL10923677 | 0.81 | — | — | |
| Piperazine SCHEMBL4608549 | 0.81 | KDM4E (0.37) | MEN1KMT2A | |
| SCHEMBL17142024 | 0.77 | MEN1 (0.35) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL14142190 | 0.76 | SMN1; SMN2 (0.35) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL13225737 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109302846-B | Indolinone compounds and their use in the treatment of fibrotic diseases | 莱斯彼维特有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-20190337929-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LIMITED (GB) | 2019-11-07 | — | — | US | claimed |
| EP-3394048-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | Respivert Limited (GB) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109513-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LIMITED (GB) | 2017-06-29 | — | — | WO | claimed |
| CN-87104734-A | Benzhydryloxyethylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | — | 1988-04-06 | — | — | CN | claimed |
| WO-2024139080-A1 | CHEMICAL MECHANICAL POLISHING COMPOSITION USED FOR EDGE POLISHING | 昂士特科技(深圳)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024139038-A1 | CHEMICO-MECHANICAL POLISHING COMPOSITION WITH IMPROVED RECYCLING PERFORMANCE | 昂士特科技(深圳)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-117903058-A | N-heterocyclic carbene ligand, preparation method and application thereof | 浙江工业大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-116254059-B | Chemical mechanical polishing composition for edge polishing | 昂士特科技(深圳)有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-115926629-B | Chemical mechanical polishing composition with improved recycling properties | 昂士特科技(深圳)有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3722291-B1 | INDOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | RESPIVERT LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-6362178-B1 | TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN CILAG S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
| EP-1114046-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017195-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987265-A1 | Interleukin-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-22 | — | — | EP | disclosed |
| CN-87104734-A | Benzhydryloxyethylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | — | 1988-04-06 | — | — | CN | disclosed |
| EP-0154669-A1 | Catalyst for urethane foam blown with carboxylic acids | ABBOTT LABORATORIES (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4473666-A | A DIALKYLCYCLOHEXYLAMINE AND AN N-SUBSTITUTED ALKOXYALKYL PIPERAZINE | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | ALOX5, IL5, IL6ST | MEN1 4651/4885KMT2A 4018/4885SLC6A2 4334/4885 |
| US-20190337929-A1 | INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDO1, INMT, IDO2 | MEN1 1749/4885KMT2A 2216/4885SLC6A2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.